Drugs & Therapy Perspectives

, Volume 18, Issue 2, pp 15–18 | Cite as

Tourette syndrome: a range of therapeutic options now available

Disease Management


Morphine Attention Deficit Hyperactivity Disorder Risperidone Clonidine Cancer Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kossoff EH, Singer HS. Tourette syndrome: clinical characteristics and current management strategies. Paediatr Drugs 2001; 3 (5): 355–63PubMedCrossRefGoogle Scholar
  2. 2.
    Hanna PA, Janjua FN, Constant CF, et al. Bilineal transmission in Tourette syndrome. Neurology 1999; 53: 813–8PubMedCrossRefGoogle Scholar
  3. 3.
    Mason A, Banerjee S, Eapen V, et al. The prevalence of Tourette syndrome in a mainstream school population. Dev Med Child Neurol 1998 May; 40 (5): 292–6PubMedGoogle Scholar
  4. 4.
    Jankovic J. Tourette’s syndrome. N Engl J Med 2001 Oct; 345 (16): 1184–92PubMedCrossRefGoogle Scholar
  5. 5.
    Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette disorder. Am J Psychiatry 1997; 8: 1057–62Google Scholar
  6. 6.
    Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001; 62 (1): 50–6PubMedCrossRefGoogle Scholar
  7. 7.
    Eapen V, Robertson MM. Comorbid obsessive-compulsive disorder and Tourette syndrome: therapeutic interventions. CNS Drugs 2001 Mar; 13 (3): 173–13CrossRefGoogle Scholar
  8. 8.
    Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive compulsive disorder. J Clin Psychiatry 1999 Feb; 60 (2): 101–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations